ScreenerHero

NKTXNkarta, Inc.

NAS · US · Healthcare · Biotechnology · nkartatx.com
2.660USD+4.72%Mkt Cap: 190.52M $P/E: —

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen re…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap190.52M $
Enterprise Value67.69M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-104.08M $
Revenue/Share—
Last Price2.660 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees106
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.41
PEG—
EV/EBITDA-0.60
EV/Revenue—
P/S—
P/B0.71
EPS (TTM)-1.55
EPS (Forward)-1.75
52W Range
1.70048% of range3.715
52W High3.715 USD
52W Low1.700 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-33.33%
ROA-25.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-88.70M $
CapEx (TTM)1.21M $
FCF Margin—
FCF Yield-28.94%
Net Debt-109.22M $
Net Debt/EBITDA0.96
Balance Sheet
Debt/Equity0.24
Current Ratio7.98
Quick Ratio7.85
Book Value/Sh3.459 USD
Cash/Share2.552 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.83 USD
Upside (mean)+307.3%
Target Range9.000 USD – 14.00 USD
$9.000+307.3% to mean$14.00
# Analysts6
Ownership
Shares Out.71.62M
Float60.52M
Insiders4.88%
Institutions82.92%
Short Interest
Short Ratio4.2d
Short % Float5.81%
Short % Out.4.64%
Shares Short3.33M
Short (prev mo.)3.38M
Technical
SMA 502.616 (+1.7%)
SMA 2002.394 (+11.1%)
Beta0.94
S&P 52W Chg18.16%
Avg Vol (30d)667.02K
Avg Vol (10d)477.35K
Technical Indicators
RSI (14)59.3
MACD-0.0268
MACD Signal-0.0847
MACD Hist.+0.0578
BB Upper2.595 USD
BB Middle2.308 USD
BB Lower2.022 USD
BB Width24.79%
ATR (14)0.1704 USD
Vol Ratio (20d)1.74x